[논문]Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer

Park, Se Hoon; Breitbach, Caroline J; Lee, Jeeyun; Park, Joon Oh; Lim, Ho Yeong; Kang, Won Ki; Moon, Anne; Mun, Jae-Hee; Sommermann, Erica M; Maruri Avidal, Liliana; Patt, Rick; Pelusio, Adina; Burke, James; Hwang, Tae-Ho; Kirn, David; Park, Young Suk

doi:10.1038/mt.2015.109

[해외논문] Phase 1b Trial of Biweekly Intravenous Pexa-Vec (JX-594), an Oncolytic and Immunotherapeutic Vaccinia Virus in Colorectal Cancer 원문보기

Molecular therapy : the journal of the American Society of Gene Therapy, v.23 no.9, 2015년, pp.1532 - 1540

Park, Se Hoon , Breitbach, Caroline J , Lee, Jeeyun , Park, Joon Oh , Lim, Ho Yeong , Kang, Won Ki , Moon, Anne , Mun, Jae-Hee , Sommermann, Erica M , Maruri Avidal, Liliana , Patt, Rick , Pelusio, Adina , Burke, James , Hwang, Tae-Ho , Kirn, David , Park, Young Suk

Abstract ▼ AI-Helper

Fifteen patients with treatment-refractory colorectal cancer were enrolled on a phase 1b study of Pexa-Vec (pexastimogene devacirepvec; JX-594), an oncolytic and immunotherapeutic vaccinia designed to selectively replicate in cancer cells. Pexa-Vec was administered intravenously every 14 days, at dose levels of 1??10(6), 1??10(7), or 3??10(7) plaque-forming units (pfu)/kg. The primary endpoint was to determine the maximum tolerated dose. Secondary endpoints were pharmacokinetics and pharmacodynamics as well as antitumor activity. Patients were heavily pretreated (mean 4.5 lines of therapy). All patients received at least two Pexa-Vec doses (median = 4; range = 2-4). No dose-limiting toxicities were reported, and the maximum tolerated dose was not reached. The most common adverse events were grade 1/2 flu-like symptoms, generally lasting <24 hours. During the first and last cycles, genome pharmacokinetics were unchanged. Infectious pfu could be detected in plasma up to 2 hours after cycle 1 and up to 30 minutes after cycle 4 (when antivaccinia antibody titers are known to have peaked). Ten patients (67%) had radiographically stable disease. Given the acceptable safety profile of multiple intravenous Pexa-Vec infusions in patients with treatment-refractory colorectal cancer, further trials evaluating efficacy of intravenous Pexa-Vec, as monotherapy or in combination with chemotherapeutic agents, is warranted in this patient population.

참고문헌 (14)

J Clin Oncol Douillard 28 4697 2010 10.1200/JCO.2009.27.4860 Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: the PRIME study

상세보기
J Clin Oncol Peeters 28 4706 2010 10.1200/JCO.2009.27.6055 Randomized phase III study of panitumumab with fluorouracil, leucovorin, and irinotecan (FOLFIRI) compared with FOLFIRI alone as second-line treatment in patients with metastatic colorectal cancer

상세보기
Cancer Res Lievre 66 3992 2006 10.1158/0008-5472.CAN-06-0191 KRAS mutation status is predictive of response to cetuximab therapy in colorectal cancer

상세보기
Lancet Grothey 381 303 2013 10.1016/S0140-6736(12)61900-X Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial

상세보기
Mol Ther Parato 20 749 2012 10.1038/mt.2011.276 The oncolytic poxvirus JX-594 selectively replicates in and destroys cancer cells driven by genetic pathways commonly activated in cancers

상세보기
Mol Ther Kim 14 361 2006 10.1016/j.ymthe.2006.05.008 Systemic armed oncolytic and immunologic therapy for cancer with JX-594, a targeted poxvirus expressing GM-CSF

상세보기
Lancet Oncol Park 9 533 2008 10.1016/S1470-2045(08)70107-4 Use of a targeted oncolytic poxvirus, JX-594, in patients with refractory primary or metastatic liver cancer: a phase I trial

상세보기
Nat Med Heo 19 329 2013 10.1038/nm.3089 Randomized dose-finding clinical trial of oncolytic immunotherapeutic vaccinia JX-594 in liver cancer

상세보기
Nature Breitbach 477 99 2011 10.1038/nature10358 Intravenous delivery of a multi-mechanistic cancer-targeted oncolytic poxvirus in humans

상세보기
Eur J Clin Invest Hovgaard 22 45 1992 10.1111/j.1365-2362.1992.tb01934.x Clinical pharmacokinetic studies of a human haemopoietic growth factor, GM-CSF

상세보기
Cancer Res McCart 61 8751 2001 Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes

상세보기
Cancer Res Kirn 68 2071 2008 10.1158/0008-5472.CAN-07-6515 Enhancing poxvirus oncolytic effects through increased spread and immune evasion

상세보기
BMC Cancer Heinemann 11 221 2011 10.1186/1471-2407-11-221 Synergistic effects of oncolytic reovirus and docetaxel chemotherapy in prostate cancer

상세보기
Mol Ther Liu 16 1637 2008 10.1038/mt.2008.143 The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma

상세보기

활용도 분석정보

상세보기

다운로드

내보내기

활용도 Top5 논문

해당 논문의 주제분야에서 활용도가 높은 상위 5개 콘텐츠를 보여줍니다.
더보기 버튼을 클릭하시면 더 많은 관련자료를 살펴볼 수 있습니다.

원문 보기

AccessON 원문보기

원문 URL 링크

DOI : 10.1038/mt.2015.109 [무료]
PubMed Central : 저널 > 논문 [무료]
Cell Press_ScienceDirect : 저널
AccessON : 저널

*원문 PDF 파일 및 링크정보가 존재하지 않을 경우 KISTI DDS 시스템에서 제공하는 원문복사서비스를 사용할 수 있습니다.

오픈액세스(OA) 유형

GOLD(Hybrid)

저자가 APC(Article Processing Charge)를 지불한 논문에 한하여 자유로운 이용이 가능한, hybrid 저널에 출판된 논문

이 논문과 함께 이용한 콘텐츠

저작권 관리 안내

내보내기 메뉴

내보내기 구분

파일저장
인쇄
메일전송

구성항목

기본정보
상세정보

관리번호, 논문명, 저널/프로시딩명, 저자 , 발행년, 권, 호, 시작페이지, 끝페이지, 발행기관

저장형식

Text(ASCII format)
Excel format
RefWorks Direct Export
RIS format (for Reference Manager, ProCite, EndNote), Scholar's Aids, Mendeley

메일정보

받는사람 (필수): @
보내는사람 (선택): @
제목
내용: KISTI 검색결과 이메일 서비스

안내

총 건의 자료가 검색되었습니다.

다운받으실 자료의 인덱스를 입력하세요. (1-10,000)

검색결과의 순서대로 최대 10,000건 까지 다운로드가 가능합니다.

데이타가 많을 경우 속도가 느려질 수 있습니다.(최대 2~3분 소요)

다운로드 파일은 UTF-8 형태로 저장됩니다.
파일의 내용이 제대로 보이지 않을실 때는 웹브라우저 상단의 보기 -> 인코딩 -> 자동선택 여부를 확인하십시오.

Text(ASCII format)
Excel format

표제어: PCR

동의어: Packet Collision Rate

용어 설명 출처 목록 (6)

용어 설명: PCR은 세균 특이성이 있는 primer를 이용하여 적은 수의 세균이 있을지라도 쉽게 검출할 수 있는 유용한 방법이며, 이를 이용하여 구강 내 치면세균막이나 타액에서 직접 세균을 검출할 수 있게 되었다[8].

AI-Helper ※ AI-Helper는 을 사용합니다.

AI-Helper

안녕하세요, AI-Helper입니다. 좌측 "선택된 텍스트"에서 텍스트를 선택하여 요약, 번역, 용어설명을 실행하세요.
※ AI-Helper는 부적절한 답변을 할 수 있습니다.

연합인증